AGR2 and breast cancer: Congruently, the knockdown of the AGR2 protein using siRNAs or clustered regularly interspaced short palindromic repeat technology in several cell lines, namely, the lung adenocarcinoma cell lines A549 and H1299, the estrogen receptor-positive breast cancer cell lines BT-474 and MCF7, the pancreatic cancer cell line PANC-1 and the embryonic kidney epithelial cell line HEK-293, resulted in the decreased ability of the cancer cells to adhere [79].